Brief: Moleculin Miracle Trial Delivers 40% Preliminary Blinded CRc Rate (N=30)
18/02/2026 14:13
Feb 18 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN MIRACLE TRIAL DELIVERS 40% PRELIMINARY BLINDED CRC RATE (N=30) MOLECULIN BIOTECH INC - REPORTS 40% PRELIMINARY CRC RATE IN MIRACLE TRIAL MOLECULIN BIOTECH INC - EXPECTS RECRUITMENT OF FIRST 45 SUBJECTS BY Q1 2026 MOLECULIN BIOTECH INC - BLINDED EFFICACY RATES IN MIRACLE TRIAL ENCOURAGING Source text: ID:nGNX4DJ9zs Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM